{"nctId":"NCT00829413","briefTitle":"SonoVue®-Enhanced Ultrasound (US) Versus Unenhanced US for Focal Liver Lesion Characterization","startDateStruct":{"date":"2010-06"},"conditions":["Liver Neoplasms"],"count":353,"armGroups":[{"label":"Patients who received SonoVue","type":"OTHER","interventionNames":["Drug: SonoVue®"]}],"interventions":[{"name":"SonoVue®","otherNames":["sulfur hexafluoride microbubbles"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Male/female.\n* Provides written Informed Consent and is willing to comply with protocol requirements.\n* Is at least 18 years of age.\n* Has at least 1 FLL (target lesion) requiring work-up for characterization. Target lesions may include those:\n\nIncidentally detected, In subjects with chronic hepatitis or liver cirrhosis, In subjects with known history of malignancy.\n\n* Is scheduled for surgical removal or biopsy of the target lesion from 24 hours to 30 days after the SonoVue® administration OR\n* In case tissue biopsy is not indicated nor surgery planned, is scheduled for or has performed a CE-CT and/or CE-MRI of the target lesion from 30 days to 48 hours prior to or from 24 hours to 30 days after the administration of SonoVue®.\n\nExclusion Criteria:\n\n* Has an acoustic window insufficient for adequate ultrasound examination of the liver.\n* Has a FLL that cannot be identified with unenhanced ultrasound.\n* Has received or is scheduled for antineoplastic chemotherapy or an invasive procedure in the time period between test procedures and truth standard assessments which may have modified the target lesion.\n* Is receiving any other contrast medium, within the 48 hours before and up to 24 hours following the administration of SonoVue®.\n* Has previously been enrolled in and completed this study.\n* Known right to left cardiac shunt, bidirectional or transient.\n* Has any known allergy to 1 or more of the ingredients of the investigational product (sulfur hexafluoride or to any components of SonoVue®).\n* Has any contraindication to 1 of the planned imaging procedures (ultrasound, CT or MRI), e.g., implants, claustrophobia, inadequate medical conditions etc.\n* Has received an investigational compound within 30 days before admission into this study.\n* Has any medical condition or other circumstances which would significantly decrease the chances of obtaining reliable data, achieving study objectives, or completing the study and/or post-dose follow-up examinations.\n* Is determined by the Investigator that the subject is clinically unsuitable for the study.\n* Is a pregnant or lactating female. Exclude the possibility of pregnancy by:\n\ntesting on site at the institution serum βHCG within 24 hours prior to the start of SonoVue® administration, surgical history (e.g., tubal ligation or hysterectomy), post menopausal with a minimum 1 year without menses.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Sensitivity: Percentage of True Positive Lesions Among All Malignant Lesions Per Truth Standard","description":"Sensitivity of SonoVue-enhanced ultrasound (SonoVue CE-US) versus unenhanced ultrasound (UE-US) for characterization of malignant focal liver lesions (FLLs) using the diagnosis provided by each of the 3 off-site assessors (blinded to patient data) for the Intent-to-diagnose (ITD) population. Unit of analysis was the lesion, equivalent to subject, since each subject had a single lesion to be characterized.\n\nTrue positive: subject with a target lesion characterized as malignant by both ultrasonography and the truth standard.\n\nTruth standard: CE-CT and/or CE-MRI examination OR tissue pathology/histology from surgical resection/biopsy OR 6-month follow up Calculated as (number of true positive lesions/number of malignant lesions per truth standard) x 100","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"48.7","spread":null},{"groupId":"OG001","value":"86.6","spread":null},{"groupId":"OG002","value":"35.3","spread":null},{"groupId":"OG003","value":"75.6","spread":null},{"groupId":"OG004","value":"16.0","spread":null},{"groupId":"OG005","value":"91.6","spread":null}]}]}]},{"type":"PRIMARY","title":"Specificity: Percentage of True Negative Lesions Among All Benign Lesions Per Truth Standard'","description":"Specificity of SonoVue-enhanced versus unenhanced ultrasound for characterization of benign FLLs, using the diagnosis provided by each of the 3 off-site assessors (blinded to patient data) for the ITD population.\n\nUnit of analysis was the lesion, equivalent to the subject, since each subject had a single lesion that was to be characterized.\n\nTrue negative: subject with a target lesion characterized as benign by both ultrasonography and truth standard.\n\nAmong the 259 ITD participants, only 140 participants (lesions) were benign based on the truth standard.\n\nTruth standard: CE-CT and /or CE-MRI examination OR tissue pathology/histology from surgical resection/biopsy OR 6-month follow up. Calculated as (number of true negative lesions/number of benign lesions per truth standard) x 100.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"62.9","spread":null},{"groupId":"OG001","value":"70.7","spread":null},{"groupId":"OG002","value":"54.3","spread":null},{"groupId":"OG003","value":"82.9","spread":null},{"groupId":"OG004","value":"22.1","spread":null},{"groupId":"OG005","value":"72.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Accuracy: Percentage of True Positive and True Negative Among All Lesions","description":"Accuracy of SonoVue-enhanced versus unenhanced ultrasound for characterization of malignant and benign FLLs, using the diagnosis provided by each of the 3 off-site assessors (blinded to patient data) for the ITD population.\n\nUnit of analysis was the lesion, equivalent to the subject, since each subject had a single lesion that was to be characterized.\n\nTrue positive: subject with a target lesion characterized as malignant by both ultrasonography and truth standard.\n\nTrue negative: subject with a target lesion characterized as benign by both ultrasonography and truth standard.\n\nTruth standard: CE-CT and /or CE-MRI examination OR tissue pathology/histology from surgical resection/biopsy OR 6-month follow up. Calculated as (number of true positive and true negative lesions/number of total lesions per truth standard) x 100.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"56.4","spread":null},{"groupId":"OG001","value":"78.0","spread":null},{"groupId":"OG002","value":"45.6","spread":null},{"groupId":"OG003","value":"79.5","spread":null},{"groupId":"OG004","value":"19.3","spread":null},{"groupId":"OG005","value":"81.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Positive Predictive Value [PPV]: Percentage of True Positive Lesions Among All Malignant Lesions Per Ultrasound","description":"Positive Predictive Value of SonoVue-enhanced versus unenhanced ultrasound for characterization of FLLs, using the diagnosis provided by each of the 3 off-site assessors (blinded to patient data) for the ITD population. Unit of analysis was the lesion, equivalent to the subject, since each subject had a single lesion that was to be characterized.\n\nTrue positive: subject with a target lesion characterized as malignant by both ultrasonography and truth standard.\n\nTruth standard: CE-CT and /or CE-MRI examination OR tissue pathology/histology from surgical resection/biopsy OR 6-month follow up.\n\nCalculated as (number of true positive lesions/number of malignant lesions per ultrasound) x 100.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"52.7","spread":null},{"groupId":"OG001","value":"71.5","spread":null},{"groupId":"OG002","value":"39.6","spread":null},{"groupId":"OG003","value":"78.9","spread":null},{"groupId":"OG004","value":"14.8","spread":null},{"groupId":"OG005","value":"74.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Negative Predictive Value [NPV]: Percentage of True Negative Lesions Among All Benign Lesions Per Ultrasound","description":"Negative Predictive Value of SonoVue-enhanced versus unenhanced ultrasound for characterization of FLLs, using the diagnosis provided by each of the 3 off-site assessors (blinded to patient data) for the ITD population. Unit of analysis was the lesion, equivalent to the subject, since each subject had a single lesion that was to be characterized.\n\nTrue negative: subject with a target lesion characterized as benign by both ultrasonography and truth standard.\n\nTruth standard: CE-CT and /or CE-MRI examination OR tissue pathology/histology from surgical resection/biopsy OR 6-month follow up. Calculated as (number of true negative lesions/number of benign lesions per ultrasound) x 100.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"59.1","spread":null},{"groupId":"OG001","value":"86.1","spread":null},{"groupId":"OG002","value":"49.7","spread":null},{"groupId":"OG003","value":"80.0","spread":null},{"groupId":"OG004","value":"23.7","spread":null},{"groupId":"OG005","value":"91.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Specific Diagnosis of Malignant FLLs","description":"SonoVue-enhanced versus unenhanced ultrasound for specific diagnosis of malignant FLLs, using the diagnosis provided by each of the 3 off-site assessors (blinded to patient data) for the ITD population. Unit of analysis was the lesion, equivalent to the subject, since each subject had a single lesion that was to be characterized.\n\nTruth standard: CE-CT and /or CE-MRI examination OR tissue pathology/histology from surgical resection/biopsy OR 6-month follow up. Calculated as (number of correctly characterized lesions/number of lesions per truth standard) x 100.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"47","spread":null},{"groupId":"OG001","value":"47","spread":null},{"groupId":"OG002","value":"47","spread":null},{"groupId":"OG003","value":"47","spread":null},{"groupId":"OG004","value":"47","spread":null},{"groupId":"OG005","value":"47","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"16","spread":null},{"groupId":"OG001","value":"26","spread":null},{"groupId":"OG002","value":"10","spread":null},{"groupId":"OG003","value":"29","spread":null},{"groupId":"OG004","value":"3","spread":null},{"groupId":"OG005","value":"30","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"47","spread":null},{"groupId":"OG001","value":"47","spread":null},{"groupId":"OG002","value":"47","spread":null},{"groupId":"OG003","value":"47","spread":null},{"groupId":"OG004","value":"47","spread":null},{"groupId":"OG005","value":"47","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"18","spread":null},{"groupId":"OG001","value":"37","spread":null},{"groupId":"OG002","value":"12","spread":null},{"groupId":"OG003","value":"31","spread":null},{"groupId":"OG004","value":"1","spread":null},{"groupId":"OG005","value":"28","spread":null}]}]}]},{"type":"SECONDARY","title":"Specific Diagnosis of Benign FLLs","description":"SonoVue-enhanced versus unenhanced ultrasound for specific diagnosis of benign FLLs, using the diagnosis provided by each of the 3 off-site assessors (blinded to patient data) for the ITD population. Unit of analysis was the lesion, equivalent to the subject, since each subject had a single lesion that was to be characterized.\n\nAmong the 140 ITD participants with benign lesions based on the truth standard, only 91 participants (lesions) were characterized as either hemangioma or focal nodular hyperplasia.\n\nTruth standard: CE-CT and /or CE-MRI examination OR tissue pathology/histology from surgical resection/biopsy OR 6-month follow up. Calculated as (number of correctly characterized lesions/number of lesions per truth standard) x 100.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"52","spread":null},{"groupId":"OG001","value":"52","spread":null},{"groupId":"OG002","value":"52","spread":null},{"groupId":"OG003","value":"52","spread":null},{"groupId":"OG004","value":"52","spread":null},{"groupId":"OG005","value":"52","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"28","spread":null},{"groupId":"OG001","value":"38","spread":null},{"groupId":"OG002","value":"30","spread":null},{"groupId":"OG003","value":"43","spread":null},{"groupId":"OG004","value":"12","spread":null},{"groupId":"OG005","value":"38","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"39","spread":null},{"groupId":"OG001","value":"39","spread":null},{"groupId":"OG002","value":"39","spread":null},{"groupId":"OG003","value":"39","spread":null},{"groupId":"OG004","value":"39","spread":null},{"groupId":"OG005","value":"39","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"15","spread":null},{"groupId":"OG001","value":"23","spread":null},{"groupId":"OG002","value":"8","spread":null},{"groupId":"OG003","value":"22","spread":null},{"groupId":"OG004","value":"2","spread":null},{"groupId":"OG005","value":"18","spread":null}]}]}]},{"type":"SECONDARY","title":"Inter-reader Agreement","description":"Kappa statistic based on assessment of malignant or benign by unenhanced and SonoVue-enhanced ultrasonography separately and computation for the percentage agreement within two categories: \"3 out of 3 readers agree\" and \"2 out of 3 readers agree\".","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"28.2","spread":null},{"groupId":"OG001","value":"66.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"94.6","spread":null},{"groupId":"OG001","value":"99.6","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":4,"n":340},"commonTop":["Nausea","Headache","Diarrhea","Flatulence","Dizziness"]}}}